Alpelisib

Common brands: Piqray, Vijoice, Faslodex, Cligavyx, Fulvestrant

Top reporter: Novartis Pharmaceuticals Corporation

Estrogen Receptor Antagonist [EPC]Aromatase Inhibitor [EPC]Kinase Inhibitor [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]RANK Ligand Inhibitor [EPC]
8,554
Total Reports
5,292
Serious Reports
1,217
Death Reports
30
Reported Reactions
Death Report Ratio: High (14.23%)

Patient Demographics

Male
437
Female
7,318

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Alpelisib.

# Reaction Reports % of Total
1 HYPERGLYCAEMIA 1,503
10.4%
2 RASH 1,387
9.6%
3 DIARRHOEA 1,343
9.3%
4 BLOOD GLUCOSE INCREASED 1,120
7.7%
5 DEATH 890
6.2%
6 NAUSEA 857
5.9%
7 FATIGUE 844
5.8%
8 DECREASED APPETITE 546
3.8%
9 WEIGHT DECREASED 520
3.6%
10 MALIGNANT NEOPLASM PROGRESSION 502
3.5%
11 VOMITING 480
3.3%
12 DRUG INEFFECTIVE 372
2.6%
13 ASTHENIA 343
2.4%
14 STOMATITIS 341
2.4%
15 PRURITUS 277
1.9%
16 PYREXIA 269
1.9%
17 DIABETES MELLITUS 244
1.7%
18 BREAST CANCER METASTATIC 242
1.7%
19 PAIN 242
1.7%
20 DISEASE PROGRESSION 225
1.6%
21 ALOPECIA 220
1.5%
22 MALAISE 218
1.5%
23 DRY MOUTH 205
1.4%
24 DYSPNOEA 196
1.4%
25 DEHYDRATION 195
1.3%
26 HEADACHE 191
1.3%
27 OFF LABEL USE 186
1.3%
28 METASTASES TO BONE 176
1.2%
29 METASTASES TO LIVER 171
1.2%
30 HYPERSENSITIVITY 152
1.1%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.